Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06115135 · ClinicalTrials.gov registry record · Phase 2

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

A Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Oncotherapeutics.

Recruiting
Registry status
Phase 2
Development phase
39
Enrollment target
2
Study locations

NCT06115135 is a Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory that is actively recruiting participants, run by Oncotherapeutics. The registered enrollment target is 39 participants, below the 48-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (19% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06115135, a Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, is actively recruiting participants, sponsored by Oncotherapeutics.

RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
2
Study locations

Study Summary

A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

Conditions Studied

Multiple Myeloma in Relapse Multiple Myeloma, Refractory

Interventions

  • DRUG Venetoclax

Study Locations (2)

California

  • Berenson Cancer Center - West Hollywood

Nebraska

  • Nebraska Cancer Specialists - Omaha

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2024-06-20
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

Oncotherapeutics

17 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06115135

The ClinicalTrials.gov registry entry for NCT06115135 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (19% lower). The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 1 intervention - of which Venetoclax is the first listed.

NCT06115135 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Nebraska.

Frequently Asked Questions

What is clinical trial NCT06115135 about?

NCT06115135 is a clinical study titled "A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma". A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

What is the current status of trial NCT06115135?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-06-20. Estimated completion is 2027-12-31.

What conditions does trial NCT06115135 study?

This clinical trial studies the following conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.

What interventions are being tested in trial NCT06115135?

The interventions under investigation include: Venetoclax (DRUG).

Who is sponsoring clinical trial NCT06115135?

This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06115135 being conducted?

This trial has 2 study locations across California, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma in Relapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma in Relapse

All registered trials for this condition

Multiple Myeloma, Refractory

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.